GenePrex has obtained positive results from a pre-clinical test on lung cancer nano development. It contains a tumor suppressor gene encoded in a cholesterol nanoparticle.
Genprex announced that in collaboration with the Anderson University of Texas Center, it has been able to conduct a pre-test on its new nanoparticle and has achieved positive results. This drug, called encoprex, can be used to treat lung cancer.
In year 4, Genprex Corporation signed a partnership agreement with the Anderson Center to partner with the Center to develop a drug for cancer treatment. This drug uses a substance called TUSC1, a type of tumor suppressor. This active ingredient is a flagship product of Geneprex, which is combined with autoimmune methods.
Researchers have shown that TUSC1 is a tumor suppressor gene that has very few side effects and has less side effects than traditional lung cancer drugs.
The company puts the TUSC1 gene in a cholesterol nanoparticle and uses it as engineered material to target cancer cells. At the American Cancer Research Association meeting, researchers at the Anderson Center presented the results of the test in a poster entitled Development of an improved humanized patient-derived xenograft, Hu-PDX, mouse model for antitumor immune response in lung cancer.
In the poster, the researchers showed that the combination of the TUSC1 gene with another drug had a great effect on the treatment of lung cancer, which increased the survival rate of mice bearing cancer cells. These data indicate that this treatment can significantly reduce the growth of cancer tumors.
“This very sophisticated model brings us one step closer to using the immune system against cancer, which has been done successfully on animal models,” says Julian Pham, a company spokesman for Geneprex. “These results enable us to evaluate our hypotheses about how the immune system interacts with a tumor after the drug is injected into the body.”
This post is also available in: Persian